Home › Calculator › IKT Dividend Calculator 2026
IKT Dividend Calculator 2026
No dividendHealthcareInhibikase Therapeutics, Inc. · NASDAQ
Price: $1.52 · Annual div: None · Frequency: — · Payout ratio: N/A · Ex-div: —
Calculator settings
IKT is not a dividend-focused stock
IKT pays a very low or no dividend (Yield: 0.00%). This calculator is designed for income-producing assets. If your goal is passive income and compounding, you might want to look at these popular alternatives:
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
IKT Dividend Yield
Inhibikase Therapeutics, Inc. (IKT) does not currently pay a regular dividend in our data, so its dividend yield is 0%.
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When IKT pays your bills
Year your monthly dividend income covers each expense (based on current settings)
About Inhibikase Therapeutics, Inc. (IKT) — Dividend Analysis 2026
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot Holding LLC, for prodrug technology development and maintains an exclusive license for IKT-001. The company was founded in 2008 and is headquartered in Wilmington, Delaware.
IKT Dividend & DRIP — Frequently Asked Questions
Does IKT pay a dividend?
No. Inhibikase Therapeutics, Inc. (IKT) has not paid a regular dividend in the last 12 months in our data, so its dividend yield is 0% and it produces no dividend income.
How can I get dividend income instead of IKT?
Dividend ETFs such as SCHD, VYM or JEPI pay regular income. Open their DRIP calculators to see what $10,000 would earn per month and how reinvesting grows it.
Does IKT have a DRIP (dividend reinvestment plan)?
A DRIP reinvests dividends into new shares. IKT has no regular dividend in our data, so there is nothing to reinvest.
Stocks similar to IKT
Forward dividend yield from the latest data · open any DRIP calculator
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full IKT DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open IKT position with:
🌍 IKT Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold IKT.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 0.00% | -2.80% | $0 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 0.00% | -2.80% | $0 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 0.00% | -2.80% | $0 / yr |
| 🇬🇧 UK ISA | 0% | 0.00% | -2.80% | $0 / yr |
| 🇬🇧 UK Taxable | 8.75% | 0.00% | -2.80% | $0 / yr |
| 🇨🇦 TFSA | 0% | 0.00% | -2.80% | $0 / yr |
| 🇨🇦 CA Taxable | 25% | 0.00% | -2.80% | $0 / yr |
| 🇦🇺 Super (pension) | 15% | 0.00% | -2.80% | $0 / yr |
| 🇦🇺 AU Taxable | 30% | 0.00% | -2.80% | $0 / yr |
| 🇩🇪 DE Taxable | 26.375% | 0.00% | -2.80% | $0 / yr |
| 🇫🇷 FR Taxable | 30% | 0.00% | -2.80% | $0 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 IKT Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
No dividend data available for this ticker.
Based on current dividend of $0.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 IKT Dividend Payment Schedule
IKT pays quarterly — 4 times per year. Ex-div: —.
📊 IKT vs Healthcare Benchmarks
How IKT compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for IKT sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ IKT Insider Activity
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| A-Award | 2026-10-19 | 310,000 | $1.65 | $509.9K | ||
| J-Other | 2026-07-29 | 18,030,000 | $0.00 | $18.0K | ||
| J-Other | 2026-07-29 | 18,030,000 | $0.00 | $18.0K | ||
| M-Exempt | 2026-07-30 | 21,854 | $1.26 | $27.5K | ||
| M-Exempt | 2026-07-30 | 21,854 | $1.26 | $27.5K | ||
| A-Award | 2026-06-26 | 155,000 | $1.91 | $296.1K | ||
| A-Award | 2026-06-26 | 155,000 | $1.91 | $296.1K | ||
| A-Award | 2026-06-26 | 155,000 | $1.91 | $296.1K | ||
| A-Award | 2026-06-26 | 155,000 | $1.91 | $296.1K | ||
| A-Award | 2026-06-26 | 155,000 | $1.91 | $296.1K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst Price Target
Wall Street consensusAnalyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Peer Group
Similar companies in the same sectorCompare IKT with peers: IKT vs AGEN · IKT vs ATOS · IKT vs CGTX
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the IKT dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Inhibikase Therapeutics, Inc. (IKT) is currently trading at $1.52, 42% below its 52-week high. It does not currently pay a regular dividend.
Does IKT Pay a Dividend? Inhibikase Therapeutics, Inc. Dividend Status
Inhibikase Therapeutics, Inc. (IKT) is a healthcare stock trading at $1.52. It does not currently pay a regular dividend in our data, so it produces no dividend income and DRIP reinvestment does not apply. Investors seeking income often look at dividend ETFs such as SCHD, VYM or JEPI instead.
- Without a dividend, returns depend entirely on the share price.
Auto-generated from live market data. For educational purposes only — not financial advice.
Latest IKT News
LiveNews aggregated from public sources via Finnhub & RSS. For informational purposes only.
Projected your IKT DRIP returns?
If DividendFlow helped you see your future dividend income clearly, other investors deserve the same clarity. Your review takes 30 seconds and makes a real difference.